Correction: Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor

Oncotarget. 2018 Oct 16;9(81):35283. doi: 10.18632/oncotarget.26252.

Zexi Hu^{1

2}, Yong Hu^{1

2}, Xicheng Liu², Rongwen Xi², Aiqun Zhang³, Deruo Liu⁴, Qiang Xie⁵, Liang Chen^{2

6}

¹ College of Life Sciences, Beijing Normal University, Beijing, China.
² National Institute of Biological Sciences, Beijing, China.
³ The General Hospital of People's Liberation Army (301 hospital), Beijing, China.
⁴ Department of thoracic surgery, China-Japan Friendship Hospital, Beijing, China.
⁵ Fuzhou Pulmonary Hospital of Fujian, Fujian, China.
⁶ National Institute of Biological Sciences, Collaborative Innovation Center for Cancer Medicine, Beijing, China.

Abstract

[This corrects the article DOI: 10.18632/oncotarget.5221.].